BiotechTube
Gamma Diagnostics

Gamma Diagnostics

San Diego, United States· Est.
gammadiagnostics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.4M

Overview

Gamma Diagnostics is a private, commercial-stage diagnostics company specializing in the Gamma Prime Fibrinogen (GPF) biomarker. Its core product is the GammaCoeur test kit, designed to predict thrombotic risk and inflammation severity in cardiovascular disease and conditions like COVID-19. The company leverages foundational research from its founder and aims to empower clinicians with better predictive tools. It operates as a commercial entity selling diagnostic kits, with a leadership team experienced in diagnostics, research, and business development.

Cardiovascular DiseaseInfectious DiseaseInflammatory Conditions

Technology Platform

Proprietary assays for measuring the Gamma Prime Fibrinogen (GPF) biomarker in blood plasma to predict thrombosis and inflammation risk.

Funding History

25
Total raised:$10.4M
Grant$278K
Grant$112K
Grant$112K
Grant$118K

Opportunities

Significant opportunity to expand the use of its GPF biomarker beyond cardiovascular disease into large adjacent markets like sepsis, long-COVID, and cancer-associated thrombosis.
The growing focus on personalized medicine and predictive diagnostics creates a favorable environment for novel biomarker adoption.

Risk Factors

Primary risks include slow clinical adoption against established tests, challenges securing widespread insurance reimbursement, and competition from larger diagnostics firms that could develop competing assays.
The company's growth is heavily dependent on continued clinical validation studies.

Competitive Landscape

Competes in the crowded cardiovascular and inflammatory biomarker space against large, established players (e.g., Roche, Abbott, Siemens) offering tests for hs-CRP, D-dimer, and other markers. Its differentiation is the specificity of GPF for thrombotic risk, but it lacks the commercial scale and brand recognition of its larger rivals.

More companies in Diagnostics & Precision Medicine →More companies in United States →